[go: up one dir, main page]

WO2001083816A3 - Procedes de detection de tumeurs - Google Patents

Procedes de detection de tumeurs Download PDF

Info

Publication number
WO2001083816A3
WO2001083816A3 PCT/IB2001/000899 IB0100899W WO0183816A3 WO 2001083816 A3 WO2001083816 A3 WO 2001083816A3 IB 0100899 W IB0100899 W IB 0100899W WO 0183816 A3 WO0183816 A3 WO 0183816A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
component
detecting tumors
sample
tenascin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000899
Other languages
English (en)
Other versions
WO2001083816A2 (fr
Inventor
Dario Neri
Francesca Viti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philogen SpA
Original Assignee
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen SpA filed Critical Philogen SpA
Priority to AU58679/01A priority Critical patent/AU5867901A/en
Publication of WO2001083816A2 publication Critical patent/WO2001083816A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001083816A3 publication Critical patent/WO2001083816A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne la détection de tumeurs, y compris de tumeurs latentes, par analyse du liquide organique d'un individu. En particulier, l'invention concerne la détermination de la présence ou de l'absence, dans un échantillon de liquide organique, d'un ARN messager (mRNA) codant pour un constituant de matrice extracellulaire dans cet échantillon, lequel constituant est trouvé en particulier dans les tumeurs. Ce constituant peut être de la fibronectine ED-A, ED-B, ou une isoforme de grande taille de tenascine C.
PCT/IB2001/000899 2000-05-04 2001-05-03 Procedes de detection de tumeurs Ceased WO2001083816A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58679/01A AU5867901A (en) 2000-05-04 2001-05-03 Method for detecting tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20186400P 2000-05-04 2000-05-04
US60/201,864 2000-05-04

Publications (2)

Publication Number Publication Date
WO2001083816A2 WO2001083816A2 (fr) 2001-11-08
WO2001083816A3 true WO2001083816A3 (fr) 2003-03-13

Family

ID=22747609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000899 Ceased WO2001083816A2 (fr) 2000-05-04 2001-05-03 Procedes de detection de tumeurs

Country Status (2)

Country Link
AU (1) AU5867901A (fr)
WO (1) WO2001083816A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501946C (fr) 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions et methodes de detection du virus du nil occidental
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP2142567B1 (fr) 2007-04-02 2013-01-16 Philogen S.p.A. L' antigène ed-a du fibrinogene est associé à la néovasculature de métastases tumorales
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PL3281952T3 (pl) 2007-10-30 2020-11-16 Philogen S.P.A. Antygen związany z reumatoidalnym zapaleniem stawów
WO2010078950A2 (fr) 2009-01-07 2010-07-15 Philogen S.P.A. Antigènes associés à l'endométriose, au rhumatisme psoriasique et au psoriasis
EP2461832B1 (fr) 2009-08-05 2017-06-28 Philogen S.p.A. Ciblage de la néovascularisation de la moelle osseuse
CN104768563B (zh) 2012-10-03 2020-02-28 菲罗根股份公司 与炎性肠病有关的抗原
WO2017084017A1 (fr) * 2015-11-16 2017-05-26 合肥立方制药股份有限公司 Utilisation de protéine ed-b dans le diagnostic d'une hyperplasie tissulaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (fr) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Diagnostic et therapie du cancer
US5981218A (en) * 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
WO2000052204A2 (fr) * 1999-02-22 2000-09-08 Orntoft Torben F Expression genique dans les tumeurs de la vessie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (fr) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Diagnostic et therapie du cancer
US5981218A (en) * 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
WO2000052204A2 (fr) * 1999-02-22 2000-09-08 Orntoft Torben F Expression genique dans les tumeurs de la vessie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBRECHT MARTIN ET AL: "Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance.", HISTOCHEMISTRY AND CELL BIOLOGY, vol. 112, no. 1, July 1999 (1999-07-01), pages 51 - 61, XP002218305, ISSN: 0948-6143 *
MICHELL A J ET AL: "HUMAN TENASCIN-C: IDENTIFICATION OF A NOVEL TYPE III REPEAT IN ORAL CANCER AND OF NOVEL SPLICE VARIANTS IN NORMAL, MALIGNANT AND REACTIVE ORAL MUCOSAE", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 72, 1997, pages 236 - 240, XP000937664, ISSN: 0020-7136 *
NICOLO G ET AL: "EXPRESSION OF TENASCIN AND OF THE ED-B CONTAINING ONCOFETAL FIBRONECTIN ISOFORM IN HUMAN CANCER", CELL DIFFERENTIATION AND DEVELOPMENT, vol. 32, no. 3, 1990, pages 401 - 408, XP008009720, ISSN: 0922-3371 *
OYAMA FUMITAKA ET AL: "Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors.", CANCER RESEARCH, vol. 53, no. 9, 1993, pages 2005 - 2011, XP002218306, ISSN: 0008-5472 *
VOLLMER G ET AL: "EXPRESSION OF TENASCIN-C BY HUMAN ENDOMETRIAL ADENOCARCINOMA AND STROMA CELLS: HETEROGENEITY OF SPLICE VARIANTS AND INDUCTION BY TGF-BETA", BIOCHEMISTRY AND CELL BIOLOGY. BIOCHIMIE ET BIOLOGIE CELLULAIRE, XX, XX, vol. 75, 1997, pages 759 - 769, XP000937670, ISSN: 0829-8211 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Also Published As

Publication number Publication date
WO2001083816A2 (fr) 2001-11-08
AU5867901A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
EP1700912A4 (fr) Methode de detection d'une molecule cible au moyen d'un aptamere
WO2004063753A3 (fr) Marqueur serique pour mesurer une cirrhose du foie
WO2004099432A3 (fr) Identification de biomarqueurs permettant de detecter la presence d'un cancer du pancreas
WO2008041953A3 (fr) Diagnostic et traitement de la dingue
WO2007064567A3 (fr) Dispositif et procede permettant de mesurer la corrosion en temps reel
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
WO2002097415A3 (fr) Instruments d'analyse, biocapteurs et methodes associees
WO2005113817A3 (fr) Conjugues nanoparticules-aptameres, et leur procede d'utilisation pour detecter un analyte cible
WO2006020579A3 (fr) Procede d'identification rapide de micro-organismes
AU2003238869A1 (en) Hybrid microcantilever sensors
IL181131A0 (en) USE OF C3a AND DERIVATIVES THEREOF AS A BIOMARKER FOR COLORECTAL ADEMONA AND/OR CARCINOMA; DIAGNOSIS METHOD AND TEST SYSTEM USING THE SAME
ATE520986T1 (de) Proteasenachweis
WO2008060651A8 (fr) Sparc et procédés d'utilisation de celui-ci
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
WO2006002243A3 (fr) Procedes de profilage d'oligosaccharides pour la detection du cancer
WO2001055719A3 (fr) Kit de diagnostic permettant de detecter des niveaux de creatine
WO2001083816A3 (fr) Procedes de detection de tumeurs
WO2004057341A3 (fr) Dosage permettant d'indiquer un risque de maladie cardiovasculaire
WO2008030186A8 (fr) Biomolécules diagnostiques
WO2004057336A3 (fr) Utilisation de la nicotinamide n-methyltransferase comme marqueur du cancer colorectal
MX2021016095A (es) Nuevo marcador de diagnostico para cancer pancreatico.
WO2006001931A3 (fr) Prouroguanyline, analogues synthetiques ou produits de clivage proteolytiques derives de celle-ci servant d'agents therapeutiques ou diagnostiques pour des maladies impliquant une homeostasie de sel et/ou d'eau
WO2003057014A3 (fr) Biomarqueurs destines a la detection du cancer de l'ovaire
WO2003091695A3 (fr) Identification de marqueurs biologiques pour la detection du cancer de la prostate
WO2003076896A3 (fr) Utilisation de biomarqueurs pour detecter le cancer du sein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP